Pulse Biosciences to Participate in Upcoming Investor Conferences

Pulse Biosciences to Participate in Upcoming Investor Conferences

HAYWARD, Calif.–(BUSINESS WIRE)–
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in three upcoming virtual investor conferences.

Management is scheduled to present at the Stifel Healthcare Conference on Tuesday, November 17, 2020 at 4:00pm ET.

Management is scheduled to present at the Stephens Annual Investment Conference on Thursday, November 19, 2020 at 4:00pm ET.

Management is also scheduled to participate in the Piper Sandler Healthcare Conference hosting one-on-one meetings Tuesday, December 1, 2020. A presentation webcast will be available in advance of the event on Monday, November 23, 2020 at 10:00am ET.

Interested parties may access a live and recorded webcast from all conferences on the “Investors” section of the Company’s website at www.pulsebiosciences.com.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across a spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Investors:

Pulse Biosciences

Sandra Gardiner, EVP and CFO

510.241.1077

[email protected]

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

[email protected]

Media:

Tosk Communications

Nadine D. Tosk

504.453.8344

[email protected] or

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Medical Devices Health

MEDIA:

CTG to Participate at Upcoming Virtual Investor Conferences

BUFFALO, N.Y., Nov. 11, 2020 (GLOBE NEWSWIRE) — CTG (NASDAQ: CTG), a leading provider of information technology (IT) solutions and services in North America and Western Europe, today announced that management will be available to meet with participating investors at the following virtual investor conferences.

The
Benchmark Discovery One-on-One Conference

Participation Date: Wednesday, November 18, 2020

The Sidoti Virtual Microcap Conference

Participation Date: Thursday, November 19, 2020
Webcast: A replay of the presentation will be available at investors.ctg.com

Portfolio managers and analysts can request a virtual meeting with the Company by contacting their sales representative at the respective hosting firms.

About CTG

CTG has established a reputation for responsiveness and reliability—traits that our clients say set us apart—since our founding in 1966. Today, we provide comprehensive information, technology, and business solutions that address critical challenges for clients in high-growth industries in North America and Western Europe. Backed by a proven track record of reliable delivery, CTG fosters long-term client relationships and trust, which allows us to develop strategic insights that maximize client investments in solutions and competitive advantage. CTG has operations in North America, South America, Western Europe, and India. The Company regularly posts news and other important information online at www.ctg.com.

Investors and Media:

John M. Laubacker, Chief Financial Officer
(716) 887-7368

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET

HOUSTON, Nov. 11, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with pediatric cancers, solid tumors and other cancers, today reported its corporate and financial results for the third quarter ended September 30, 2020.

Recent Business and Corporate Events:

  • Ewing sarcoma Phase 1/2 clinical trial is completing dose escalation to establish maximum tolerated dose (MTD) and is expected to advance into Phase 2 dose-expansion in Q1 2021
  • Ewing sarcoma clinical trial expansion phase expanded to include patients with Ewing-related sarcomas such as myxoid liposarcoma, desmoplastic small round cell tumors and other sarcomas with similar biology to Ewing sarcoma
     º Ewing sarcoma and Ewing-related sarcomas represent rare cancers affecting both children and adults where there is a high unmet need for additional treatment options

Financial Highlights:

  • Total cash and cash equivalents of $9.6 million as of September 30, 2020 due in part to $6.2 million gross proceeds in an underwritten public offering closed August 3, 2020
  • Three-month period ended September 30, 2020 net loss per common share – basic and diluted – of $0.10, compared to $0.73 for the same period ended September 30, 2019

“The events of the third quarter of 2020 affirm the company’s growth strategy and demonstrate the potential of seclidemstat as a treatment for cancers with high unmet need,” said David Arthur, President and CEO of Salarius. “Our lead clinical program in Ewing sarcoma continues to advance, and we expect to reach the maximum tolerated dose (MTD) in the Phase 1 portion of the clinical trial and, as planned, begin the Phase 2 dose-expansion portion of the trial in Q1 2021.  This is an important milestone as it allows us to establish the recommended Phase 2 dosing regimen for the trial and begin treating a broader group of patients with Ewing and Ewing-related sarcomas.”

Mr. Arthur continued, “Ewing sarcoma and advanced solid tumors (AST) remain our most advanced development programs, but we believe seclidemstat offers the opportunity to address numerous cancers where additional treatment options are needed.  In this regard, we recently expanded the dose-expansion phase of the Ewing sarcoma clinical trial to include several additional sarcomas.  This decision was based on preclinical data and early clinical data observations from the ongoing clinical trials that suggest seclidemstat may demonstrate drug activity and have applicability in other sarcomas that have a similar gene arrangement to Ewing sarcoma, known as Ewing-related sarcomas.  Among those observations, Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions, which generally represent a patient’s largest measurable tumors.”

Ewing Sarcoma Clinical Trial Expanded
On July 29, 2020, Salarius announced the expansion of its ongoing Phase 1/2 clinical trial of seclidemstat in Ewing sarcoma to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas.  Sarcomas of interest include myxoid liposarcoma, desmoplastic small round cell tumors and other sarcomas that harbor similar FET family gene rearrangements to Ewing sarcoma.

These Ewing-related sarcomas were chosen based on their underlying biology as well as preclinical data and early clinical observations involving seclidemstat that suggest the drug may demonstrate activity and may have applicability in several sarcomas that share key characteristics of Ewing sarcoma.  As Salarius previously disclosed, a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions.  Target lesions generally represent a patient’s largest measurable tumors.  However, at eight weeks, an increase in non-target lesions resulted in an overall patient classification of progressive disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).

The amendment to the ongoing clinical trial will allow up to 30 patients with Ewing-related sarcomas to enroll in the trial’s upcoming dose-expansion phase, which is in addition to the 20 Ewing sarcoma patients also planned to be treated in the dose-expansion phase. 

Additional Clinical Trials to Expand Development Program
Mr. Arthur concluded, “In addition, in the third quarter we continued preparatory work on two additional clinical trials and look forward to announcing the initiation of these trials soon.  These additional clinical trials support our growth strategy focused on maximizing the market potential of seclidemstat.”  

Three-
Month Financial Results:
For the three-month period ended September 30, 2020, Salarius’ reported net loss was $1.7 million, or $0.10 per basic and diluted share, compared to a net loss of $2.6 million, or $0.73 per basic and diluted share for the same period in 2019.  The loss before other income for the three-month period ended September 30, 2020 decreased by $2.0 million compared to the same time span last year, primarily due to a $2.2 million decrease in general and administrative expenses which more than offset the increase of $0.7 million in research and development expenses. Increased research and development costs resulted from increased clinical trial expenses and drug manufacturing costs. The decrease in general and administrative costs resulted from the absence of costs related to Salarius’ one-time transformation into a public company during 2019 which did not reoccur in the current period.

As of September 30, 2020, total cash, cash equivalents and restricted cash were $9.6 million, compared to $3.7 million at year-end 2019. Increases in cash balances result from the Company’s public offerings of stock in the first quarter and third quarter 2020.  The Company expects its cash and cash equivalents to fund its operations into the third quarter of 2021.

$6.2 Million Underwritten Public Offering

On August 3, 2020, Salarius completed an underwritten public offering with total gross proceeds of approximately $6.2 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. Salarius intends to use the net proceeds from the offering and ongoing non-dilutive financial support from the Cancer Prevention Institute of Texas (CPRIT) to fund the expansion of the Ewing sarcoma clinical trial and ongoing company operations.

Conference Call Information:

Salarius Pharmaceuticals will host a conference call and live audio webcast on Wednesday, November 11, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the third quarter 2020.  Interested participants and investors may access the conference call by dialing either:

  • (833) 423-0481 (U.S.)
  • (918) 922-2375 (international)
  • Conference ID: 1277839

An audio webcast will be accessible via the Investors Events and Presentations section of the Company’s website http://investors.salariuspharma.com/.  An archive of the webcast will remain available for 90 days beginning at approximately 5:30 p.m. ET, on November 11, 2020.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients that need them the most.  Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).  For more information, please visit salariuspharma.com or follow the Company on Twitter and LinkedIn.

Forward-Looking Statements 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical facts, included in this press release are forward-looking statements.  These forward-looking statements may be identified by terms such as “anticipate,” “potential,” “progress,” “design,” “estimate,” “continue,” “will,” “aim,” “can,” “believe,” “plan,” “allow,” “expect,” “intend,” “goal,” “provide,” “able to,” “position,” “project,” “developing,” and similar terms or expressions or the negative thereof.  Examples of such statements include, but are not limited to, statements relating to the following: Salarius’ growth strategy; the value of seclidemstat as a potential treatment for Ewing sarcoma and other cancers; the status and anticipated progress and milestones of Salarius’ clinical trials in advanced solid tumors and Ewing sarcoma including statements related to when Salarius will reach the maximum tolerated dose in the Phase 1 portion of the study and when Salarius will begin the Phase 2 expansion portion of any study; the expansion of Salarius’ clinical trials to include Ewing-related sarcomas; Salarius’ belief as to being well-capitalized; statements related to Salarius’ ability to obtain or the availability of any additional amount from the CPRIT award; the anticipated use of proceeds from Salarius’ recent public offering to advance and expand the seclidemstat development pipeline; Salarius’ goal to maximize the potential of seclidemstat; Salarius’ developing seclidemstat for several cancers with high unmet medical need; and Salarius plans to announce two additional clinical trials. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.  You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements.  These risks and uncertainties include, but are not limited to, the following: the sufficiency of Salarius’ capital resources; the ability of, and need for, Salarius to raise additional capital to meet Salarius’ business operational needs and to achieve its business objectives and strategy; Salarius’ ability to project future capital needs and cash utilization and timing and accuracy thereof; the ability of Salarius to access the remaining funding available under the CPRIT grant; future clinical trial results and impact of results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions and regulatory or contractual restrictions which may impact the ability of Salarius to raise additional capital; the possibility of unexpected expenses or other uses of Salarius’ cash resources; risks related to the COVID-19 outbreak; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those discussed in Salarius’ quarterly report on Form 10-Q for the quarter ended June 30, 2020 and in Salarius’ annual report on Form 10-K for the year ended December 31, 2019.  The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date.  Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Contact


Tiberend Strategic Advisors, Inc.


Maureen McEnroe, CFA/Miriam Miller (investors)
(212) 375-2664 / 2694
[email protected]
[email protected]
Johanna Bennett (media)
(212) 375-2686 
[email protected]



SALARIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

  September 30,

2020
  December 31,

2019
       
Assets      
Current assets:      
Cash and cash equivalents $ 9,557,813     $ 3,738,900  
Grants receivable from CPRIT 3,212,678      
Prepaid expenses and other current assets 1,148,667     955,899  
Total current assets 13,919,158     4,694,799  
Property and equipment, net 15,635     25,016  
Goodwill 8,865,909     8,865,909  
Other assets 262,509     308,674  
Total assets $ 23,063,211     $ 13,894,398  
Liabilities and stockholders’ equity      
Current liabilities:      
Accounts payable $ 1,195,063     $ 1,790,966  
Accrued expenses and other current liabilities 448,862     160,783  
Note payable 761,096     502,332  
Deferred revenue     541,701  
Warrant liability 52,224     317,762  
Total liabilities 2,457,245     3,313,544  
       
Commitments and contingencies (Note 6)      
       
Stockholders’ equity:      
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding      
Common stock, $0.0001 par value; 100,000,000 shares authorized; 19,821,716 and 4,519,533 shares issued at September 30, 2020 and December 31, 2019, and 19,818,912 and 4,511,174 shares outstanding at September 30, 2020 and December 31, 2019, respectively 1,981     451  
Additional paid-in capital 38,265,391     22,657,103  
Accumulated deficit (17,661,406 )   (12,076,700 )
Total stockholders’ equity 20,605,966     10,580,854  
Total liabilities and stockholders’ equity $ 23,063,211     $ 13,894,398  

SALARIUS PHARMACEUTICALS, INC.

 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

  Three Months Ended

September 30 
       
  2020   2019
Revenue:      
Grant revenue $ 1,378,239     $ 874,949  
Operating expenses:      
Research and development 1,803,682     1,140,909  
General and administrative 1,333,062     3,494,205  
Total operating expenses 3,136,744     4,635,114  
Loss before other income (expense) (1,758,505 )   (3,760,165 )
Change in fair value of warrant liability 45,103     1,130,848  
Government grants and other income      
Interest income (expense), net (3,230 )   (752 )
Loss from continuing operations (1,716,632 )   (2,630,069 )
Income from discontinued operations     2,348  
Net loss $ (1,716,632 )   $ (2,627,721 )
       
Loss per common share — basic and diluted $ (0.10 )   $ (0.73 )
Weighted-average number of common shares outstanding — basic and diluted 17,968,664     3,605,913  

Getty Realty Corp. Appoints Brian Dickman as New Chief Financial Officer

Getty Realty Corp. Appoints Brian Dickman as New Chief Financial Officer

JERICHO, N.Y.–(BUSINESS WIRE)–Getty Realty Corp. (NYSE: GTY) announced today that Brian R. Dickman has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective December 14, 2020. Mr. Dickman will succeed Danion Fielding, who previously announced his intention to resign for personal reasons. Mr. Fielding will stay on as Chief Financial Officer through December 11, 2020.

“I am pleased to welcome Brian to our leadership team,” said Christopher J. Constant, Getty’s President and Chief Executive Officer. “Brian is a seasoned executive with extensive real estate experience and a track record of demonstrated leadership capabilities, which makes him an excellent addition to the Getty team.” Mr. Constant continued, “On behalf of our entire Company, I want to thank Danion for his service to Getty. We have truly valued his leadership and contributions. We wish Danion much success in his future endeavors. I anticipate a smooth transition of the CFO position and expect no disruption to the continued execution of our strategic plans.”

Mr. Dickman brings more than 15 years of REIT experience to Getty, including nearly seven years as a public company executive. Mr. Dickman is joining Getty from his current role as Executive Vice President and Chief Financial Officer of Seritage Growth Properties (NYSE:SRG). Prior to joining Seritage, Mr. Dickman was Chief Financial Officer at Agree Realty (NYSE: ADC), where he was responsible for all corporate finance, capital markets, accounting, financial reporting, treasury and investor relations activities. Prior to that role, he was a real estate investment banker covering public REITs and other real estate companies beginning at Lehman Brothers in 2005.

About Getty Realty Corp.

Getty Realty Corp. is the leading publicly traded real estate investment trust in the United States specializing in the ownership, leasing and financing of convenience store and gasoline station properties. As of September 30, 2020, the Company owned 896 properties and leased 58 properties from third-party landlords in 35 states across the United States and Washington, D.C.

Investor Relations

(516) 478-5418

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: REIT Retail Commercial Building & Real Estate Construction & Property Convenience Store

MEDIA:

GMS to Present at the Stephens Annual Investment Conference

GMS to Present at the Stephens Annual Investment Conference

TUCKER, Ga.–(BUSINESS WIRE)–
GMS Inc. (NYSE: GMS), a leading North American specialty distributor of interior building products is scheduled to present at the Stephens Annual Investment Conference on Tuesday, November 17, 2020 at 11:00 Eastern Time.

The presentation will be webcast live on the Investors section of the Company’s website at www.gms.com. Following the webcast, an archived replay will be available for approximately 90 days.

About GMS:

Founded in 1971, GMS operates a network of more than 260 distribution centers across the United States and Canada. GMS’s extensive product offering of wallboard, suspended ceilings systems, or ceilings, and complementary construction products is designed to provide a comprehensive one-stop-shop for our core customer, the interior contractor who installs these products in commercial and residential buildings.

For more information about GMS, please visit www.gms.com.

Investor Relations:

Leslie Kratcoski

770-723-3306

[email protected]

Media Relations:

770-723-3378

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Interior Design

MEDIA:

Logo
Logo

Floor & Decor Holdings, Inc. Announces Participation in the Stephens Investment Conference

Floor & Decor Holdings, Inc. Announces Participation in the Stephens Investment Conference

ATLANTA–(BUSINESS WIRE)–
Floor & Decor Holdings, Inc. (NYSE: FND) today announced that the Company is scheduled to present at the Stephens Investment Conference on Wednesday, November 18, 2020, at 10:00 am Eastern Time.

The audio portion of the presentation will be webcast live over the internet and can be accessed on the Company’s Investor Relations website, ir.flooranddecor.com. An online archive will be available on that site following the presentation.

About Floor & Decor Holdings, Inc.

Floor & Decor is a multi-channel specialty retailer operating 128 warehouse-format stores and two design centers across 30 states at the end of the third quarter of fiscal 2020. The Company offers a broad assortment of in-stock hard-surface flooring, including tile, wood, laminate/luxury vinyl plank, and natural stone along with decorative and installation accessories, at everyday low prices. The Company was founded in 2000 and is headquartered in Atlanta, Georgia.

Investor Contact:

Wayne Hood

Vice President of Investor Relations

678-505-4415

[email protected]

or

Matt McConnell

Senior Manager of Investor Relations

770-257-1374

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Interior Design Retail Other Construction & Property Home Goods Specialty Construction & Property

MEDIA:

Epizyme to Participate in Jefferies Virtual London Healthcare Conference

Epizyme to Participate in Jefferies Virtual London Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Thursday, Nov. 18, 2020 at 12:35 p.m. ET.

A live webcast of the fireside chat will be available in the investor section of the company’s website and will be archived for 60 days following the presentation.

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.

TAZVERIK® is a registered trademark of Epizyme, Inc. For full prescribing information, please visit TAZVERIK.com.

Media:

Erin Graves, Epizyme, Inc.

[email protected]

(617) 500-0615

Investors:

Alicia Davis, THRUST Strategic Communications

[email protected]

(910) 620-3302

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Savara to Present at the Jefferies Virtual London Healthcare Conference

Savara to Present at the Jefferies Virtual London Healthcare Conference

AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST.

Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company’s website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara’s website for 90 days.

About Savara

Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). AeroVanc (vancomycin hydrochloride inhalation powder) is in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis (CF). Apulmiq is a Phase 3-ready inhaled ciprofloxacin for non-CF bronchiectasis (NCFB). Savara’s strategy is to develop its pipeline products with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Savara Inc. IR & PR

Anne Erickson ([email protected])

(512) 851-1366

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

EuroDry Ltd. Reports Results for the Nine-Month Period and Quarter Ended September 30, 2020

ATHENS, Greece, Nov. 11, 2020 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three and nine-month periods ended September 30, 2020.

Third
Quarter
2020
Highlights:

  • Total net revenues of $6.8 million. Net income of $0.5 million; net income attributable to common shareholders (after a $0.4 million dividend on Series B Preferred Shares) of $0.1 million or $0.06 earnings per share basic and diluted. Adjusted net income attributable to common shareholders1 for the period was $0.1 million or $0.05 adjusted earnings per share basic and diluted.
  • Adjusted EBITDA1 was $2.8 million.
  • An average of 7.0 vessels were owned and operated during the third quarter of 2020 earning an average time charter equivalent rate of $11,873 per day.
  • The Company declared a dividend of $0.4 million on its Series B Preferred Shares. The dividend will be paid in-kind by issuing additional Series B Preferred Shares.

Nine
M
onths
2020
Highlights:

  • Total net revenues of $15.9 million. Net loss of $5.6 million; net loss attributable to common shareholders (after a $1.2 million dividend on Series B Preferred Shares) of $6.7 million or $2.97 loss per share basic and diluted. Adjusted net loss attributable to common shareholders1 for the period was $6.1 million or $2.70 adjusted loss per share basic and diluted.
  • Adjusted EBITDA1 was $1.8 million.
  • An average of 7.0 vessels were owned and operated during the first half of 2020 earning an average time charter equivalent rate of $8,927 per day.

Aristides Pittas, Chairman and CEO of
EuroDry
commented
: “During the third quarter of 2020, EuroDry benefited from gradually improving charter markets as a result of the re-opening of most economies after the pandemic-related lockdowns. Since the beginning of October and during early November, the market rates have given up some of the gains, but they remain at satisfactory levels given the increased economic uncertainty due to the second wave of the pandemic and renewed economic lockdowns, especially, in Europe.

Thus, we expect that the drybulk markets will be affected in the near term by the state of the world economies as influenced by the COVID-19 pandemic, and, in the medium term, by the low fleet growth due to historically low orderbook. Consequently, we anticipate that trade developments will be the key factor influencing the rates our vessels will earn.

To better exploit the above market trends, we are focused on reducing our capital costs and creating additional liquidity via selected debt refinancings and repayment of more expensive funding instruments in our balance sheet, and using any excess funds to renew or expand our fleet. We also continue to evaluate opportunities of using our public platform to consolidate other fleets as we believe this can offer significant appreciation potential to our shareholders and flexibility to partners joining our public platform.”

Tasos Aslidis, Chief Financial Officer of
EuroDry
commented
: “Comparing our results for the third quarter of 2020 with the same period of 2019, our net revenues decreased by about $0.9 million, due to the lower time charter equivalent rates our vessels earned as compared to the third quarter of 2019. Operating expenses, including management fees and general and administrative expenses increased by approximately $0.4 million as compared to the third quarter of 2019. This increase is mainly due to increased supply of stores and spare parts for our vessels in 2020 compared to 2019 and increased crewing costs, the latter resulting from difficulties in crew rotation due to COVID-19 related restrictions. Still, we believe that we maintain one of the lowest operating cost structures amongst the public shipping companies which is one of our competitive advantages.

Adjusted EBITDA during the third quarter of 2020 was $2.8 million compared to $2.2 million achieved for the third quarter of last year. Finally, as of September 30, 2020, our outstanding debt (excluding the unamortized loan fees) is about $52.1 million versus restricted and unrestricted cash of about $3.7 million.”

_________________________
1Adjusted EBITDA, Adjusted net income/(loss) and Adjusted earnings/(loss) per share are not recognized measurements under US GAAP (GAAP) and should not be used in isolation or as a substitute for EuroDry’s financial results presented in accordance with GAAP. Refer to a subsequent section of the Press Release for the definitions and reconciliation of these measurements to the most directly comparable financial measures calculated and presented in accordance with GAAP.

Third
Quarter
2020
Results:
For the third quarter of 2020, the Company reported total net revenues of $6.8 million representing a 11.3% decrease over total net revenues of $7.7 million during the third quarter of 2019 which was the result of the lower time charter rates our vessels earned in the third quarter of 2020 compared to the corresponding period of 2019. The Company reported net income for the period of $0.5 million and net income attributable to common shareholders of $0.1 million, as compared to a net loss of $0.4 million and a net loss attributable to common shareholders of $0.8 million for the same period of 2019. For the third quarter of 2020, a gain on bunkers resulted in positive voyage expenses of $0.4 million for the period as compared to voyage expenses of $0.7 million in the same period of 2019. Losses on derivatives of $0.2 million and drydocking expenses of $0.1 million contributed to the result for the quarter as compared to losses on derivatives of $0.6 million and drydocking expenses of $0.7 million during the third quarter of 2019. Depreciation expenses for the third quarter of 2020 amounted to $1.7 million compared to $1.6 million for the same period of 2019.

Interest and other financing costs for the third quarter of 2020 amounted to $0.6 million, compared to $0.8 million for the same period of 2019. Interest during the second quarter of 2020 was lower due to the lower average outstanding debt and the decreased Libor rates of our loans during the period as compared to the same period of last year. For the three months ended September 30, 2020, the Company recognized a marginal loss on three interest rate swaps and a $0.2 million realized loss on FFA contracts as compared to a loss on derivatives of $0.6 million for the same period of 2019, comprising of a $0.5 million loss on FFA contracts and a $0.1 million loss on one interest rate swap.

On average, 7.0 vessels were owned and operated during the third quarter of 2020 earning an average time charter equivalent rate of $11,873 per day compared to 7.0 vessels in the same period of 2019 earning on average $12,088 per day.

Adjusted EBITDA for the third quarter of 2020 was $2.8 million compared to $2.2 million achieved during the third quarter of 2019.

Basic and diluted earnings per share attributable to common shareholders for the third quarter of 2020 was $0.06 calculated on 2,279,730 basic and diluted weighted average number of shares outstanding, compared to basic and diluted earnings per share of $0.35 for the third quarter of 2019, calculated on 2,254,830 basic and diluted weighted average number of shares outstanding.

Excluding the effect on the income attributable to common shareholders for the quarter of the unrealized loss / (gain) on derivatives, the adjusted earnings per share attributable to common shareholders for the quarter ended September 30, 2020 would have been $0.05 compared to adjusted loss of $0.26 per share basic and diluted for the quarter ended September 30, 2019. Usually, security analysts do not include the above item in their published estimates of earnings per share.

First
Nine Months
2020
Results:
For the first nine months of 2020, the Company reported total net revenues of $15.9 million representing a 19.1% decrease over total net revenues of $19.6 million during the first nine months of 2019, as a result of the lower time charter rates our vessels earned in the first nine months of 2020 compared to the same period of 2019. The Company reported net loss for the period of $5.6 million and net loss attributable to common shareholders of $6.7 million, as compared to a net loss of $1.4 million and a net loss attributable to common shareholders of $2.9 million, for the first nine months of 2019. Vessel operating expenses were $8.7 million for the first nine months of 2020 as compared to $8.0 million for the first nine months of 2019 due to increased supply of stores and spare parts for our vessels in 2020 compared to 2019 and increased crewing costs resulting from difficulties in crew rotation due to COVID-19 related restrictions. Depreciation expenses for the first nine months of 2020 were $4.9 million compared to $4.8 million during the same period of 2019.

Interest and other financing costs for the first nine months of 2020 amounted to $1.9 million compared to $2.7 million for the same period of 2019. This decrease is due to the lower average outstanding debt and the decreased Libor rates of our loans in the current period compared to the same period of 2019. For the nine months ended September 30, 2020, the Company recognized a $0.5 million loss on three interest rate swaps and a $0.3 million loss on FFA contracts as compared to a gain on derivatives of $0.3 million for the same period of 2019, comprising of a $0.6 million gain on FFA contracts and a $0.3 million loss on one interest rate swap.        

On average, 7.0 vessels were owned and operated during the first nine months of 2020 earning an average time charter equivalent rate of $8,927 per day compared to 7.0 vessels in the same period of 2019 earning on average $10,750 per day. In the first nine months of 2020, two vessels underwent special survey for a total cost of $1.8 million, as compared to two vessels that underwent special survey in the first nine months of 2019 for a total cost of $1.6 million.

Adjusted EBITDA for the first nine months of 2020 was $1.8 million compared to $6.5 million achieved during the first nine months of 2019.

Basic and diluted loss per share attributable to common shareholders for the first nine months of 2020 was $2.97, calculated on 2,271,542 basic and diluted weighted average number of shares outstanding compared to $1.31 basic and diluted loss per share for the first nine months of 2019, calculated on 2,248,182 basic and diluted weighted average number of shares outstanding.

Excluding the effect on the loss attributable to common shareholders for the first nine months of the year of the unrealized loss on derivatives, the adjusted loss per share attributable to common shareholders for the nine-month period ended September 30, 2020 would have been $2.70 compared to a loss of $1.13 per share basic and diluted for the same period in 2019. As previously mentioned, usually, security analysts do not include the above item in their published estimates of earnings per share.

Fleet Profile:

The EuroDry Ltd. fleet profile is as follows:

Name Type Dwt Year
Built
Employment(*) TCE Rate ($/day)

Dry Bulk Vessels
         
EKATERINI Kamsarmax 82,000 2018 TC until Apr-21 Hire 106% of the Average Baltic Kamsarmax P5TC index (***)
XENIA Kamsarmax 82,000 2016 TC until Dec-2020 Hire 101% of the Average Baltic Kamsarmax P5TC index(***) with a floor at $11,000
ALEXANDROS P. Ultramax 63,500 2017 Guardian Navigation GMax LLC Pool Pool revenue from August 2018
EIRINI P Panamax 76,466 2004 TC until Apr-21 Hire 99%
of Average
BPI** 4TC
STARLIGHT Panamax 75,845 2004 TC until Aug-21 Hire 98.5%
of Average
BPI** 4TC
TASOS Panamax 75,100 2000 TC until Nov-20 $9,000
PANTELIS Panamax 74,020 2000 TC until Nov-20 $11,500
Total Dry Bulk Vessels 7
528
,
931
     

Note:  
(*) Represents the earliest redelivery date
(**) BPI stands for the Baltic Panamax Index; the average BPI 4TC is an index based on four time charter routes.
(***) The average Baltic Kamsarmax P5TC Index is an index based on five Panamax time charter routes.
   

Summary Fleet Data:

  3 months,   3 months,   9
months,
  9
months,
 
  ended   ended   ended   ended  
  September   September   September   September  
  30,
2019
  30,
2020
  30,
2019
  30,
2020
 
FLEET DATA                
Average number of vessels (1) 7.0   7.0   7.0   7.0  
Calendar days for fleet (2) 644.0   644.0   1,911.0   1,918.0  
Scheduled off-hire days incl. laid-up (3) 29.9   0.0   65.9   51.2  
Available days for fleet (4) = (2) – (3) 614.1   644.0   1,845.1   1,866.8  
Commercial off-hire days (5) 0.0   0.0   0.7   0.0  
Operational off-hire days (6) 2.9   6.5   15.4   7.1  
Voyage days for fleet (7) = (4) – (5) – (6) 611.2   637.5   1,829.0   1,859.7  
Fleet utilization (8) = (7) / (4) 99.5%   98.9%   99.1%   99.6%  
Fleet utilization, commercial (9) = ((4) – (5)) / (4) 100.0%   100.0%   100.0%   100.0%  
Fleet utilization, operational (10) = ((4) – (6)) / (4) 99.5%   98.9%   99.2%   99.6%  
         
AVERAGE DAILY RESULTS        
Time charter equivalent rate (11) 12,088   11,873   10,750   8,927  
Vessel operating expenses excl. drydocking expenses (12) 4,855   5,673   4,939   5,337  
General and administrative expenses (13) 867   724   900   858  
Total vessel operating expenses (14) 5,722   6,397   5,839   6,195  
Drydocking expenses (15) 1,073   82   835   931  

(1) Average number of vessels is the number of vessels that constituted the Company’s fleet for the relevant period, as measured by the sum of the number of calendar days each vessel was a part of the Company’s fleet during the period divided by the number of calendar days in that period.

(2) Calendar days. We define calendar days as the total number of days in a period during which each vessel in our fleet was in our possession including off-hire days associated with major repairs, drydockings or special or intermediate surveys or days of vessels in lay-up. Calendar days are an indicator of the size of our fleet over a period and affect both the amount of revenues and the amount of expenses that we record during that period.

(3) The scheduled off-hire days including vessels laid-up are days associated with scheduled repairs, drydockings or special or intermediate surveys or days of vessels in lay-up.

(4) Available days. We define available days as the total number of days in a period during which each vessel in our fleet was in our possession net of scheduled off-hire days incl. laid up. We use available days to measure the number of days in a period during which vessels were available to generate revenues.

(5) Commercial off-hire days. We define commercial off-hire days as days a vessel is idle without employment.

(6) Operational off-hire days. We define operational off-hire days as days associated with unscheduled repairs or other off-hire time related to the operation of the vessels.

(7) Voyage days. We define voyage days as the total number of days in a period during which each vessel in our fleet was in our possession net of commercial and operational off-hire days. We use voyage days to measure the number of days in a period during which vessels actually generate revenues or are sailing for repositioning purposes.

(8) Fleet utilization. We calculate fleet utilization by dividing the number of our voyage days during a period by the number of our available days during that period. We use fleet utilization to measure a company’s efficiency in finding suitable employment for its vessels and minimizing the amount of days that its vessels are off-hire for reasons such as unscheduled repairs or days waiting to find employment.

(9) Fleet utilization, commercial. We calculate commercial fleet utilization by dividing our available days net of commercial off-hire days during a period by our available days during that period.

(10) Fleet utilization, operational. We calculate operational fleet utilization by dividing our available days net of operational off-hire days during a period by our available days during that period.

(11) Time charter equivalent, or TCE, is a measure of the average daily net revenue performance of our vessels. Our method of calculating TCE is determined by dividing time charter revenue and voyage charter revenue net of voyage expenses by voyage days for the relevant time period. Voyage expenses primarily consist of port, canal and fuel costs that are unique to a particular voyage, which would otherwise be paid by the charterer under a time charter contract, or are related to repositioning the vessel for the next charter. TCE is a standard shipping industry performance measure used primarily to compare period-to-period changes in a shipping company’s performance despite changes in the mix of charter types (i.e., spot voyage charters, time charters, pool agreements and bareboat charters) under which the vessels may be employed between the periods. Our definition of TCE may not be comparable to that used by other companies in the shipping industry.

(12) Daily vessel operating expenses, which include crew costs, provisions, deck and engine stores, lubricating oil, insurance, maintenance and repairs and management fees are calculated by dividing vessel operating expenses by fleet calendar days for the relevant time period. Drydocking expenses are reported separately.

(13) Daily general and administrative expense is calculated by dividing general and administrative expenses by fleet calendar days for the relevant time period.

(14) Total vessel operating expenses, or TVOE, is a measure of our total expenses associated with operating our vessels. TVOE is the sum of vessel operating expenses, management fees and general and administrative expenses; drydocking expenses are not included. Daily TVOE is calculated by dividing TVOE by fleet calendar days for the relevant time period.

(15) Drydocking expenses include expenses during drydockings that would have been capitalized and amortized under the deferral method divided by the fleet calendar days for the relevant period. Drydocking expenses could vary substantially from period to period depending on how many vessels underwent drydocking during the period. The Company expenses drydocking expenses as incurred.

Conference Call and Webcast:

Tomorrow, November 12, 2020 at 10:30 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results. 

Conference Call details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (877) 553-9962 (US Toll Free Dial In), 0(808) 238- 0669 (UK Toll Free Dial In) or +44 (0) 2071 928592 (Standard International Dial In). Please quote “EuroDry” to the operator. 

A replay of the conference call will be available until November 18, 2020. The United States replay number is 1(866) 331-1332; from the UK 0(808) 238-0667; the standard international replay number is (+44) (0) 3333 00 9785 and the access code required for the replay is: 2489743#.  

Audio webcast – Slides Presentation:

There will be a live and then archived audio webcast of the conference call, via the internet through the EuroDry website (www.eurodry.gr). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. A slide presentation on the Third Quarter 2020 results in PDF format will also be available 10 minutes prior to the conference call and webcast accessible on the company’s website (www.eurodry.gr) on the webcast page. Participants to the webcast can download the PDF presentation.


EuroDry
Ltd.

Unaudited
Consolidated
Condensed Statements of Operations

(All amounts expressed in U.S. Dollars – except
number of
shares
)

  Three Months Three Months Nine
Months
Nine
Months
  Ended Ended Ended Ended
  September
30,
September
30,
September
30,
September
30,
  2019 2020 2019 2020
  (unaudited) (unaudited)
Revenues                
Time charter revenue 8,085,650   7,193,251   20,729,160   16,795,245  
Commissions (425,449)   (399,715)   (1,095,101)   (917,915)  
                 
Net revenues 7
,
660
,
201
  6
,
793
,
536
  1
9,634,059
  1
5,877,330
 
         
Operating expenses        
Voyage expenses, net 697,518   (375,866)   1,067,717   194,137  
Vessel operating expenses 2,634,821   3,135,569   7,961,650   8,744,999  
Drydocking expenses 690,989   52,685   1,595,588   1,786,008  
Vessel depreciation 1,615,947   1,651,870   4,813,165   4,904,386  
                          Related party management fees 492,065   518,161   1,476,608   1,491,665  
General and administrative expenses 558,033   466,381   1,720,091   1,646,536  
Total Operating expenses (
6,689,373)
  (
5,448,800)
  (1
8
,
634
,
819)
  (1
8
,
767
,
731)
 
         
Operating income
/ (loss)
970
,
828
  1,344
,
736
  999
,
240
  (2,890
,
401)
 
         
Other income / (expenses)        
Interest and other financing costs (848,473)   (616,219)   (2,729,021)   (1,864,040)  
(Loss) / gain on derivatives, net (568,340)   (178,760)   334,648   (821,906)  
Foreign exchange gain/(loss) 3,886   (12,336)   3,325   (8,445)  
Interest income 8,064   391   20,850   4,041  
Other expenses, net (1,404,863)   (806,924)   (
2,370,198)
  (
2,
690
,
350)
 
Net (loss) / income (434,035)   537,812   (1,370,958)   (
5
,
580
,
751)
 
Dividend Series B Preferred shares (358,726)   (407,665)   (1,390,255)   (1,155,677)  
Preferred deemed dividend     (185,665)    
Net (loss)
/
income
attributable to common shareholders
(792,761)   130,147   (2,946,878)   (
6
,
736
,
428)
 
(Loss) / earnings per share, basic and diluted (0.35)   0.06   (1.31)   (2.97)  
Weighted average number of shares, basic and diluted 2,254,830   2,279,730   2,248,182   2,271,542  


EuroDry
Ltd.

Unaudited Consolidated
Condensed Balance Sheets

(All amounts expressed in U.S. Dollars – except
number of
share
s
)

  December 31, September 30,
  2019
2020
     
ASSETS (unaudited)
Current Assets:    
Cash and cash equivalents 5,396,406   249,742  
Trade accounts receivable, net 1,843,008   1,846,273  
Other receivables 459,785   535,452  
Inventories 508,711   604,917  
Restricted cash 1,083,036   744,363  
Prepaid expenses 286,711   104,417  
Total current assets 9
,
577
,
657
  4
,
085,164
 
     
Fixed assets:    
Vessels, net 105,461,265   100,957,860  
Long-term assets:    
Restricted cash 2,650,000   2,750,000  
Total assets 117,688,922   10
7
,
793
,
024
 
     
LIABILITIES
, MEZZANINE EQUITY
AND SHAREHOLDERS’ EQUITY
   
Current liabilities:    
Long term bank loans, current portion 6,806,294   5,956,294  
Trade accounts payable 1,046,561   1,200,230  
Accrued expenses 964,423   863,343  
Accrued preferred dividends 358,726    
Derivatives   514,044  
Deferred revenue 445,824   342,839  
Due to related companies 1,547,210   1,865,122  
Total current liabilities 11,169,038   10
,
741,872
 
     
Long-term liabilities:    
Long term bank loans, net of current portion 49,688,840   45,880,368  
Derivatives 304,174   392,490  
Total long-term liabilities 49,993,014   46
,
272,858
 
Total liabilities 61,162,052   57
,
0
14
,
730
 
     
Mezzanine equity:        
Series B Preferred shares (par value $0.01, 20,000,000 preferred shares authorized, 15,387 and 16,187 shares issued and outstanding, respectively) 14,721,665   15
,
522
,
516
 
     
Shareholders’ equity:    
Common stock (par value $0.01, 200,000,000 shares authorized, 2,304,630 issued and outstanding, respectively) 23,046   23,046  
Additional paid-in capital 52,802,574   52,989,575  
Accumulated deficit (11,020,415)   (17,756,843)  
Total shareholders’ equity 41,805,205   35
,
255
,
778
 
Total liabilities
,
mezzanine
equity
and shareholders’ equity
117,688,922   107
,
793
,
024
 


EuroDry
Ltd.

Unaudited
Consolidated
Condensed Statements of Cash Flows

(All amounts expressed in U.S. Dollars)

  Nine
Months
  Nine
Months
 
  Ended   Ended  
  September
30,
  September
30,
 
  2019   2020  
         
Cash flows from operating activities:        
Net loss (1,370,958)   (5,580,751)  
Adjustments to reconcile net loss to net cash provided by operating activities:    
Vessel depreciation 4,813,165   4,904,386  
Amortization of deferred charges 117,703   105,528  
Share-based compensation 133,632   187,001  
Unrealized loss on derivatives 410,498   602,361  
Changes in operating assets and liabilities 8,856,256   370,007  

Net cash provided by operating activities
12,960,296   588,532  
     
Cash flows from investing activities:    
     
Cash paid for vessel under construction (47,562)    
Vessel improvements (961,274)   (496,316)  

Net cash used in investing activities
(1,008,836)   (
496,316)
 
     
Cash flows from financing activities:    
Redemption of preferred shares (4,300,000)    
Preferred dividends paid (952,886)   (713,553)  
Loan arrangement fees paid (22,500)    
Proceeds from long term bank loans 4,500,000    
Repayment of long term bank loans (9,959,000)   (4,764,000)  

Net cash used in financing activities
(10,734,386)   (5,477,553)  
     
Net increase / (decrease) in cash, cash equivalents and restricted cash 1,217,074   (5,385,337)  
Cash, cash equivalents and restricted cash at beginning of period 7,754,927   9,129,442  
Cash, cash equivalents and restricted cash at end of period 8
,
972
,
001
  3
,
744
,
105
 
Cash breakdown        
Cash and cash equivalents 5,605,154   249,742  
Restricted cash, current 716,847   744,363  
Restricted cash, long term 2,650,000   2,750,000  
Total cash, cash equivalents and restricted cash shown in the statement of cash flows 8
,
972
,
001
  3
,
744
,
105
 



EuroDry

Ltd.

Reconciliation of Net
income
/ (loss)
to Adjusted EBITDA

(All amounts expressed in U.S. Dollars)

  Three Months
Ended

September
30,

2019
Three Months
Ended

September
30,

2020
Nine
Months
Ended

September
30,

2019
Nine
Months
Ended

September
30,

2020
Net (loss) / income (434,035)   537,812   (1,370,958)   (5,580,751)  
Interest and other financing costs, net (incl. interest income) 840,409   615,828   2,708,171   1,859,999  
Vessel depreciation 1,615,947   1,651,870   4,813,165   4,904,386  
Unrealized loss / (gain) on Forward Freight Agreement derivatives 147,750   (1,590)   49,350   130,380  
Loss on interest rate swap derivatives 47,085   16,559   339,602   527,735  
                 
Adjusted EBITDA 2,217,156   2,820,479   6,539,330   1
,
841
,
749
 

Adjusted EBITDA Reconciliation:

EuroDry Ltd. considers Adjusted EBITDA to represent net income / (loss) before interest, income taxes, depreciation, unrealized (gain) / loss on Forward Freight Agreements (FFAs) and (gain) / loss on interest rate swaps. Adjusted EBITDA does not represent and should not be considered as an alternative to net income / (loss), as determined by United States generally accepted accounting principles, or GAAP. Adjusted EBITDA is included herein because it is a basis upon which the Company assesses its financial performance because the Company believes that this non-GAAP financial measure assists our management and investors by increasing the comparability of our performance from period to period by excluding the potentially disparate effects between periods of, financial costs, unrealized (gain) / loss on FFAs and (gain) / loss on interest rate swaps, and depreciation. The Company’s definition of Adjusted EBITDA may not be the same as that used by other companies in the shipping or other industries. 



EuroDry

Ltd.

Reconciliation of
Net
income
/ (loss)
to Adjusted net
income
/ (loss)

(All amounts expressed in U.S. Dollars – except share data and
number of
share
s
)

  Three Months
Ended

September
30,

2019
Three Months
Ended

September
30,

2020
Nine
Months
Ended

September
30,

2019
Nine
Months
Ended

September
30,

2020
Net (loss) / income (434,035)   537,812   (1,370,958)   (5,580,751)  
Unrealized loss / (gain) on derivatives 200,837   (14,648)   410,498   602,361  
Adjusted net (loss)
/ income
(233,198)   52
3,
164
  (960,460)   (
4,978
,
390)
 
Preferred dividends (358,726)   (407,665)   (1,390,255)   (1,155,677)  
Preferred deemed dividend     (185,665)    
                 
Adjusted
net (loss) / income
attributable
to common shareholders
(591,924)   115
,
499
  (2,536,380)   (
6
,
134
,
067)
 
Adjusted (loss) / earnings per share, basic and diluted (0.26)   0.05   (1.13)   (2.70)  
Weighted average number of shares, basic and diluted 2,254,830   2,279,730   2,248,182   2,271,542  

Adjusted net
(loss) /
income and Adjusted
(loss) /
earnings per share Reconciliation:

EuroDry Ltd. considers Adjusted net (loss) / income to represent net (loss) / income before unrealized loss/ (gain) on derivatives which includes FFAs and interest rate swaps. Adjusted net (loss) / income and Adjusted (loss) / earnings per share is included herein because we believe it assists our management and investors by increasing the comparability of the Company’s fundamental performance from period to period by excluding the potentially disparate effects between periods of unrealized loss/ (gain) on derivatives, which may significantly affect results of operations between periods. Adjusted net (loss) / income and Adjusted (loss) / earnings per share do not represent and should not be considered as an alternative to net (loss) / income or (loss) / earnings per share, as determined by GAAP. The Company’s definition of Adjusted net (loss) / income and Adjusted (loss) / earnings per share may not be the same as that used by other companies in the shipping or other industries.

About
EuroDry
Ltd.

EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd into a separate listed public company. EuroDry was spun-off from Euroseas Ltd on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. 

EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day-to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

The Company has a fleet of 7 vessels, including 4 Panamax drybulk carriers, 1 Ultramax drybulk carrier and 2 Kamsarmax drybulk carriers. EuroDry’s 7 drybulk carriers have a total cargo capacity of 528,931 dwt.

Forward Looking Statement

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy; including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to changes in the demand for dry bulk vessels, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

Visit our website www.eurodry.gr

Company Contact

Tasos Aslidis
Chief Financial Officer
EuroDry Ltd.
11 Canterbury Lane,
Watchung, NJ07069
Tel. (908) 301-9091
E-mail: aha@eurodry.gr
Investor Relations / Financial Media

Nicolas Bornozis
President
Capital Link, Inc.
230 Park Avenue, Suite 1536
New York, NY10169
Tel. (212) 661-7566
E-mail: [email protected]

SenesTech Restructures Board for Commercial Growth

Three Directors Added to the Board

PR Newswire

PHOENIX, Nov. 11, 2020 /PRNewswire/ — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, today announced that it has elected three new directors to its Board of Directors, in a move to position the Board to best support the commercial growth of ContraPest®, SenesTech’s lead fertility control product.

“All three have unique and complementary skills to best support SenesTech in its current commercial growth strategies,” said Dr. Jamie Bechtel, SenesTech’s Chair.

Phil Grandinetti, III, is Founder and Chief Customer Officer for WITHit, a growth leader in Wearable Tech Accessories, with prior executive sales experience at GSM Products and LightWedge. Mr. Grandinetti brings a deep background in the commercialization of innovative consumer products and a track record of leading exponential growth.

K.C. Kavanagh is the Senior Vice President and Global Chief Communications Officer at Bacardi Limited with prior executive communications experience at Starwood Hotels & Resorts Worldwide, Inc. Ms. Kavanagh has particular expertise in strategic communications including corporate, brand and product messaging, taking complex messages and making them understandable and exciting.

Jake Leach is the Chief Technology Officer at Dexcom, a leader in continuous glucose monitoring technology, and known for pairing novel technology with an exceptional user experience. This pairing of technology and user experience is expected to have direct relevance to the commercial development of ContraPest.

In addition, the Company announced that Dr. Julie Williams will be stepping down as a Director, but will remain as Director Emeritus with Board observer rights, to provide essential continuity in this board transition.

About SenesTech 

SenesTech is changing the model for pest management by targeting one of the root causes of the problem: reproduction.

ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. Forward looking statements include, but are not limited to, our expectation regarding sales commitments, our expectation regarding the conversion of sales commitments and programs to revenue, our belief that our product is more humane, less harmful to the environment and more effective than traditional methods, and our belief that ContraPest will establish a new paradigm in rodent control without environmental effects of rodenticides.  All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT: 

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, [email protected]

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/senestech-restructures-board-for-commercial-growth-301171251.html

SOURCE SenesTech, Inc.